Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | DSP-5336 |
Synonyms | |
Therapy Description |
DSP-5336 binds to Menin (MEN1) and inhibits its interaction with MLL (KMT2A), potentially leading to decreased growth of tumor cells harboring MLL (KMT2A) rearrangements or NPM1 mutations (Blood (2021) 138 (Supplement 1): 3339). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
DSP-5336 | DSP 5336|DSP5336 | MEN1-KMT2A Inhibitor 8 | DSP-5336 binds to Menin (MEN1) and inhibits its interaction with MLL (KMT2A), potentially leading to decreased growth of tumor cells harboring MLL (KMT2A) rearrangements or NPM1 mutations (Blood (2021) 138 (Supplement 1): 3339). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04988555 | Phase Ib/II | DSP-5336 | A Study of DSP-5336 in Relapsed/Refractory AML/ ALL With or Without MLL Rearrangement or NPM1 Mutation | Recruiting | USA | ITA | FRA | ESP | CAN | BEL | 4 |